Lyell Immunopharma's CEO on the future of TIL and CAR-T therapies for solid tumor targets

blonca9
Feb 26, 2024
1 min read

On the heels of a historic recent approval for the class, Lynn Seely describes the science behind TIL therapies and how Lyell is manufacturing its products to improve potency. Plus, a discussion on ROR1 as a solid tumor target for CAR-T.

Recent Posts

See All

Cambridge, UK based Maxion Therapeutics raised a $72M series A in March to advance its KnotBody programs - which combine the benefits of knottins and antibodies and can target ion channels and GPCRs

ASGCT 2025: HuidaGene presented preclinical and early clinical data for its CRISPR Cas12 based program for DMD in a Presidential Symposium talk

ASGCT 2025: Dyno Therapeutics' CEO Eric Kelsic discusses the latest in capsids for CNS, ophthalmology, and neuromuscular conditions

Lyell Immunopharma's CEO on the future of TIL and CAR-T therapies for solid tumor targets

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight